secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001193125-25-137432
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam reports positive AD biomarker data from BROADWAY; p-tau217 reduced in ITT and ApoE4 carriers
--------------------------------------------------------------------------------

- Statistically significant lower absolute change in p-tau217 over 12 months vs placebo in full ITT (p<0.002) and ApoE4 carriers (p=0.0215).
- AD sub-study included 1,727 patients, 367 ApoE4 carriers; primary measure was p-tau217 change.
- Company plans to present full results at AAIC conference in Toronto in July 2025.
- Results build on prior genetic, preclinical, and Phase 2a data supporting CETP inhibition for AD prevention.
- Obicetrapib is an oral CETP inhibitor primarily developed for LDL-C reduction; safety shown in large trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525137432/0001193125-25-137432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525137432/d74901d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-137432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer